Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Analysts feel the company’s profit potential is starting to improve following a year in which its shares fell by more than 21%.
Investors and analysts have given it some thought and mostly think it’s a sensible acquisition.
Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly.
resTORbio is developing novel therapies to improve immune function in the elderly.
The rumors have caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Speculation around a possible bid has mounted in recent months.
The Suzhou-based cancer-drug maker has been discussing a valuation of more than $1 billion.
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Lilly’s CEO noted at JPM that the recent tax changes should free up cash for more M&As.